Avanza Healthcare vs TIN Ny Teknik

Avanza Healthcare vs TIN Ny Teknik

1. Avanza Healthcare

  • Security

    Avanza Healthcare by Samuelsson & Hult

  • Fee

    1.25%

  • ISIN

    SE0019912502

  • Holdings

    25

2. TIN Ny Teknik

  • Security

    TIN Ny Teknik A

  • Fee

    1.50%

  • ISIN

    SE0012193019

  • Holdings

    10

Fund Holdings

We have information about 28 holdings in Avanza Healthcare, where the largest holding is UnitedHealth (8.79), followed by Eli Lilly (7.45) and Novo Nordisk (6). In comparison with TIN Ny Teknik, we have 10 holdings where Surgical Science is the largest holding (7.39), followed by Novo Nordisk (5.98) and ChemoMetec (5.92).

All Holdings

Here we compare the holdings in Avanza Healthcare and TIN Ny Teknik.

Avanza Healthcare TIN Ny Teknik
1. UnitedHealth Group Inc
USA
8.79 %
1. Surgical Science Sweden AB
Sweden
7.39 %
2. Eli Lilly and Co
USA
7.45 %
2. Novo Nordisk B
Denmark
5.98 %
3. Novo Nordisk B
Denmark
6 %
3. ChemoMetec
Denmark
5.92 %
4. Merck & Co Inc
Germany
5.71 %
4. Paradox Interactive AB
Sweden
5.85 %
5. AstraZeneca
Sweden UK
4.46 %
5. Qt Group Plc
Finland
5.12 %
6. Thermo Fisher Scientific Inc
4.44 %
6. Epidemic Sound Holdings AB
Sweden
5.11 %
7. Amgen Inc
3.69 %
7. BioGaia B
Sweden
5.06 %
8. Boston Scientific Corp
3.36 %
8. Fortnox AB
Sweden
5.02 %
9. Stryker Corp
3.29 %
9. Evolution Gaming Group AB
Sweden
4.6 %
10. Novartis AG
Switzerland
3.02 %
10. Sectra B
Sweden
4.45 %
11. Cencora Inc
USA
2.91 %
-
12. Vertex Pharmaceuticals Inc
2.87 %
-
13. Regeneron Pharmaceuticals Inc
2.84 %
-
14. AbbVie Inc
USA
2.83 %
-
15. Gilead Sciences Inc
USA
2.73 %
-
16. Takeda Pharmaceutical Co Ltd
Japan
2.56 %
-
17. Dexcom Inc
USA
2.01 %
-
18. Daiichi Sankyo Co Ltd
Japan
1.76 %
-
19. IQVIA Inc
1.73 %
-
20. Terumo Corp
1.27 %
-
21. Edwards Lifesciences Corp
1.22 %
-
22. Neurocrine Biosciences Inc
1.17 %
-
23. Pfizer Inc
USA
1.16 %
-
24. Sartorius AG PRF Perpetual EUR
1.13 %
-
25. Ionis Pharmaceuticals Inc
1.08 %
-

The list of fund holdings was last updated on April 17, 2025.